Addex Therapeutics Ltd (ADXN)
8.77
-0.23
(-2.56%)
USD |
NASDAQ |
May 16, 16:00
8.77
0.00 (0.00%)
After-Hours: 20:00
Addex Therapeutics Enterprise Value: 5.016M for May 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 15, 2024 | 5.016M |
May 14, 2024 | 5.497M |
May 13, 2024 | 5.369M |
May 10, 2024 | 5.380M |
May 09, 2024 | 4.963M |
May 08, 2024 | 5.016M |
May 07, 2024 | 5.176M |
May 06, 2024 | 5.176M |
May 03, 2024 | 4.963M |
May 02, 2024 | 4.856M |
May 01, 2024 | 4.065M |
April 30, 2024 | 3.573M |
April 29, 2024 | 3.456M |
April 26, 2024 | 12.60M |
April 25, 2024 | 11.87M |
April 24, 2024 | 12.02M |
April 23, 2024 | 15.43M |
April 22, 2024 | 16.00M |
April 19, 2024 | 16.83M |
April 18, 2024 | 17.80M |
April 17, 2024 | 18.91M |
April 16, 2024 | 19.55M |
April 15, 2024 | 21.85M |
April 12, 2024 | 22.73M |
April 11, 2024 | 23.35M |
Date | Value |
---|---|
April 10, 2024 | 24.51M |
April 09, 2024 | 25.22M |
April 08, 2024 | 18.75M |
April 05, 2024 | 14.50M |
April 04, 2024 | 12.90M |
April 03, 2024 | 11.86M |
April 02, 2024 | 9.548M |
April 01, 2024 | 9.291M |
March 28, 2024 | 9.078M |
March 27, 2024 | 8.597M |
March 26, 2024 | 8.276M |
March 25, 2024 | 8.003M |
March 22, 2024 | 7.923M |
March 21, 2024 | 8.329M |
March 20, 2024 | 8.436M |
March 19, 2024 | 8.260M |
March 18, 2024 | 8.201M |
March 15, 2024 | 7.913M |
March 14, 2024 | 7.378M |
March 13, 2024 | 7.207M |
March 12, 2024 | 7.902M |
March 11, 2024 | 7.966M |
March 08, 2024 | 7.688M |
March 07, 2024 | 5.486M |
March 06, 2024 | 5.112M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-9.505M
Minimum
Jun 28 2022
87.48M
Maximum
Dec 24 2020
15.08M
Average
9.343M
Median
Enterprise Value Benchmarks
AC Immune SA | 230.96M |
CRISPR Therapeutics AG | 2.729B |
NLS Pharmaceutics Ltd | -- |
Molecular Partners AG | -100.61M |
MoonLake Immunotherapeutics | 2.021B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -3.224M |
Revenue (Quarterly) | 0.1731M |
Total Expenses (Quarterly) | 3.200M |
EPS Diluted (Quarterly) | -4.062 |
Profit Margin (Quarterly) | -1.86K% |
Earnings Yield | -212.8% |
Normalized Earnings Yield | -206.57 |